RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology
Source: PR Newswire (US)
MARLBOROUGH, Mass., July 21, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today that it will present a poster at the 2016 Summer Meeting of the American Academy of Dermatology (AAD). This meeting will bring together the best minds in dermatology to be immersed in an innovative program that includes presentations by renowned experts on topics that impact dermatologists today. The Summer AAD meeting will be held July 28-31, 2016 at the Hynes Convention Center in Boston, MA.
On Friday, July 29, 2016, at 2:40 p.m. EDT, during the Infection-Viral Poster Session, Dr. Karen Bulock, RXi's Vice President of Research will give an oral presentation entitled, "Diphenylcyclopropenone Ointment for the Treatment of Common Warts". Diphenylcyclopropenone (DPCP) is a potent topical immunotherapy agent that has been used since the late 1970's by physicians for the treatment of common warts, alopecia areata, and cutaneous metastases of melanoma. As DPCP has not yet been evaluated and approved by a regulatory agency, RXi Pharmaceuticals has developed Samcyprone™, a therapeutic consisting of a proprietary ointment formulation of DPCP based on technology that was licensed from Hapten Pharmaceuticals. A summary of the proof of concept study and an update on the status of the Company's ongoing Phase 2 study for cutaneous warts, RXI-SCP-1502, will be provided.
The poster will be available under the "Investors – Presentations & Posters" section of the Company's website, www.rxipharma.com approximately 1 hour following the presentation.
